00808nas a2200313   4500000000100000000000100001008004100002100001700043700001500060700001700075700002000092700001500112700001400127700001500141700001700156700001900173700001500192700001700207700001600224700001100240700001600251700001700267700001400284700001700298245014900315300001000464490000600474022001400480       2020                            d1 aH. Heerspink1 aA. Karasik1 aM. Thuresson1 aC. Melzer-Cohen1 aG. Chodick1 aK. Khunti1 aJ. Wilding1 aL. Rodriguez1 aL. Cea-Soriano1 aS. Kohsaka1 aA. Nicolucci1 aG. Lucisano1 aF. Lin1 aC . Y. Wang1 aE. Wittbrodt1 aP. Fenici1 aM. Kosiborod00aKidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study  a27-350 v8  a2213-8587